Estimating capital and operational costs of backhoe shovels

Material loading is one of the most critical operations in earthmoving projects. A number of different equipment is available for loading operations. Project managers should consider different technical and economic issues at the feasibility study stage and try to select the optimum type and size of equipment fleet, regarding the production needs and project specifications. The backhoe shovel is very popular for digging, loading and flattening tasks. Adequate cost estimation is one of the most critical tasks in feasibility studies of equipment fleet selection. This paper presents two different cost models for the preliminary and detailed feasibility study stages. These models estimate the capital and operating cost of backhoe shovels using uni-variable exponential regression (UVER) as well as multi-variable linear regression (MVLR), based on principal component analysis. The UVER cost model is suitable for quick cost estimation at the early stages of project evaluation, while the MVLR cost function, which is more detailed, can be useful for the feasibility study stage. Independent variables of MVLR include bucket size, digging depth, dump height, weight and power. Model evaluations show that these functions could be a credible tool for cost estimations in prefeasibility and feasibility studies of mining and construction projects

Evaluation of Major Psychiatric Disorders in Patients in Rafsanjan, Iran, with Acne Vulgaris

Background: Skin health and mental health are highly correlated. Considering that less attention has been paid to multidisciplinary fields, we evaluated the prevalence of mental disorders and related problems in patients with acne vulgaris in the city of Rafsanjan, Iran.Methods: This was a cross-sectional study. The study population included all patients with acne vulgaris in Rafsanjan who were referred in 2016 to a skin and hair clinic. After the patients agreed to participate, they underwent a psychological interview. Using the Hamilton Anxiety Scale, Beck Depression Inventory, and suicide questionnaires, their data were recorded and collected. Data were then analyzed using the chi-square test and Fisher’s exact test.Results: Of 100 patients evaluated (48 women and 52 men), 8% had severe anxiety, 61% had moderate anxiety, and 31% had mild anxiety. Moreover, 64% of patients had mild depression, 29% had moderate depression, and 7% had severe depression. Of all patients, only one had a high risk for suicide attempts. We did not find any significant relationship between anxiety or suicide disorder and any of following variables: marital status, disease duration, amount of lesions, location of lesions, and expansion of lesions. We observed that with increasing duration of illness, expansion of lesions, and level of lesions, depression increased significantly in patients with acne vulgaris. Location of lesions was not associated with depression.Conclusion: The prevalence of anxiety and depression is high in patients with acne vulgaris. Acne disease is more significantly correlated with depression

Opium Induces Apoptosis in Jurkat Cells

Background: The direct effect of some opioids on immune cells has been demonstrated. The aim of this study was to assess the apoptotic effect of opium on Jurkat T lymphocyte cells. Methods: Different concentrations of opium (2.86 × 10-3 to 2.86 × 10-11 g/ml) were added to 24-well plates containing 5 × 105 Jurkat cells. Apoptotic events were assessed after 6, 24, and 72 hours by flow-cytometric detection of surface phosphatidylserine. Findings: Significant differences in apoptosis of Jurkat cells were seen at 24 and 72 hours in different concentrations of opium (P < 0.05). After 72 hours, significant increase in necrosis of Jurkat cells was seen in opium concentration of 2.85 × 10-3 g/ml compared to cells without opium (control) (P < 0.05). Conclusion: These results showed that opium directly increases apoptosis and necrosis of T lymphocytes. This effect may play a role in immune dysfunction in opium addicts.Keywords: Opium, Apoptosis, Necrosis, Jurkat cell

Non – Detection of HPV DNA in Prostatic Cancer and Benign Prostatic Hyperplasia: a case- control study in Kerman

Background: Different studies assessed the role of inflammation in malignancy of different organs. Prostatitis has been suggested as a cause of cancer and BPH. Till now, more than 100 types of human Papilloma virus (HPV) are recognized including low and high-risk groups for carcinogenesis. Among them HPV-16 and HPV-18 have shown further association with cancer. Regarding the presence of E6 and E7 in HPV and ability for modification of basal epithelial cells, related role in prostate cancer (as well as cervical and genital malignancies) is hypothesized. The aim of this study was to determine the association of HPV-16 and HPV-18 with prostate cancer and malignancy degree. Methods: A total of 75 consecutive paraffin-embedded blocks including 50 samples with primary prostate cancer and 25 samples with benign prostate hyperplasia (BPH) as control were studied. Amplisense kit was used for replication at real-time polymerase chain reaction (PCR) to determine genotypes of HPV-16 and HPV-18. DNA purity was assessed by Nano Drop. Results: The results of real-time PCR demonstrated that none of the samples of BPH and prostate cancer had amplification of HPV DNA. Conclusion: The results revealed that HPV-16 and HPV-18 are not causes of prostate cancer

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic

Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026

Background The COVID-19 pandemic highlighted gaps in health surveillance systems, disease prevention, and treatment globally. Among the many factors that might have led to these gaps is the issue of the financing of national health systems, especially in low-income and middle-income countries (LMICs), as well as a robust global system for pandemic preparedness. We aimed to provide a comparative assessment of global health spending at the onset of the pandemic; characterise the amount of development assistance for pandemic preparedness and response disbursed in the first 2 years of the COVID-19 pandemic; and examine expectations for future health spending and put into context the expected need for investment in pandemic preparedness. Methods In this analysis of global health spending between 1990 and 2021, and prediction from 2021 to 2026, we estimated four sources of health spending: development assistance for health (DAH), government spending, out-of-pocket spending, and prepaid private spending across 204 countries and territories. We used the Organisation for Economic Co-operation and Development (OECD)'s Creditor Reporting System (CRS) and the WHO Global Health Expenditure Database (GHED) to estimate spending. We estimated development assistance for general health, COVID-19 response, and pandemic preparedness and response using a keyword search. Health spending estimates were combined with estimates of resources needed for pandemic prevention and preparedness to analyse future health spending patterns, relative to need. Findings In 2019, at the onset of the COVID-19 pandemic, US$9·2 trillion (95$7·3 trillion (95% UI 7·2–7·4) in 2019; 293·7 times the $24·8 billion (95$43·1 billion in development assistance was provided to maintain or improve health. The pandemic led to an unprecedented increase in development assistance targeted towards health; in 2020 and 2021, $1·8 billion in DAH contributions was provided towards pandemic preparedness in LMICs, and$37·8 billion was provided for the health-related COVID-19 response. Although the support for pandemic preparedness is 12·2% of the recommended target by the High-Level Independent Panel (HLIP), the support provided for the health-related COVID-19 response is 252·2% of the recommended target. Additionally, projected spending estimates suggest that between 2022 and 2026, governments in 17 (95% UI 11–21) of the 137 LMICs will observe an increase in national government health spending equivalent to an addition of 1% of GDP, as recommended by the HLIP. Interpretation There was an unprecedented scale-up in DAH in 2020 and 2021. We have a unique opportunity at this time to sustain funding for crucial global health functions, including pandemic preparedness. However, historical patterns of underfunding of pandemic preparedness suggest that deliberate effort must be made to ensure funding is maintained

Investigating the Impact of Social Capital on Team Innovation with the Mediating Role of Knowledge Sharing (Case Study: Isfahan Tuka Steel Co.)

Today’s organizations need innovation and teamwork for survival and one of the pre-requisites for innovation is the attention to social capital and human resources in the organization. Therefore, the present study investigates the impact of structural, cognitive and communication social capital on team innovation through knowledge sharing, in Tuka Steel holding company. This research belongs to descriptive-correlational researches and conducted by survey method. The statistical population of the study consisted of 400 employees of Tuka Steel holding company in Isfahan. The sample was 196 people based on Morgan’s table. This sample was selected through simple random sampling method. 192 respondents completed the questionnaire. Validity of questionnaire was confirmed by experts and its reliability was confirmed by Cronbach’s alpha of 0.769. Based on the results obtained by analyzing the data by structural equation modeling, it was determined that the dimensions of social capital, both indirectly and indirectly, through knowledge sharing, had a positive and significant impact on the innovation of the employees

Economic Evaluation and Sensitivity-Risk Analysis of Zarshuran Gold Mine Project

Zarshuran gold deposit, with the total reserves of some 12.5 million tons of 4.18 g/ton ore, is considered to be an important gold mining project in the area. In this paper the feasibility studies of the whole project is carried out on the basis of several economic variables. Given that mining data are often of uncertain nature, these economic variables have therefore been estimated under the conditions of uncertainty. The resultant Net Present Value is hence also obtained under the same conditions. For this purpose, a model is first devised with the help of Excel and COMFAR software. The model is then developed that considers different scenarios which would result in different expected values for the economic variables. It is concluded that the NPV of the project is most sensitive to gold and silver price and that other variables such as discount rate, operating and capital cost all affect the feasibility of the project with lower degree of severity. Finally, risk analysis is also carried out using Mont Carlo technique, in order to estimate the most probable value of NPV. The average NPV calculated in this way is US$49.7 Million, whilst without due consideration of risk, this would be US$ 36.6 Million. The techniques used, together with the procedures adopted in this paper, can be used in feasibility studies of all mining projects. Such decision would result in more accurate Net Present Values than expected from other frequently used methods